Acute Myeloid Leukemia Market - By Disease (Myeloblastic, Myelomonocytic, Promyelocytic), Treatment (Chemotherapy, Targeted Therapy), Route of Administration (Oral, Parenteral), End-user (Hospital, Clinic, Specialty Center) & Forecast 2024 – 2032

Acute Myeloid Leukemia Market - By Disease (Myeloblastic, Myelomonocytic, Promyelocytic), Treatment (Chemotherapy, Targeted Therapy), Route of Administration (Oral, Parenteral), End-user (Hospital, Clinic, Specialty Center) & Forecast 2024 – 2032

Acute Myeloid Leukemia Market Size

Acute Myeloid Leukemia Market was valued at USD 2.1 billion in 2023 and is estimated to grow at a CAGR of 10.7% between 2024. High market growth can be attributed to factors such as advancement in research and technology, surging government initiatives and policies, early diagnosis coupled with efforts to implement screening programs. Also, increasing prevalence of acute myeloid leukemia (AML) is a significant factor driving the growth of the market.
 

For instance, according to the American Cancer Society, in 2023, there were about 20,380 new cases of acute myeloid leukemia (AML) in the U.S. alone. Hence, as the population ages, the incidence of AML tends to rise, contributing to a larger patient pool seeking diagnosis and treatment, thereby fostering the market growth.
 

Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally develop into red blood cells, white blood cells, and platelets. In AML, these abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells.
 

Acute Myeloid Leukemia Market Trends

• Surging government initiatives and polices play a pivotal role in driving the acute myeloid leukemia industry. Also, increased government funding for medical research, including acute myeloid leukemia research, drive advancements in understanding the molecular basis of AML, leading to the development of innovative therapies and treatment modalities.
   
• For instance, The National Cancer Institute (NCI), in 2023, has funded USD 43.3 million to Ohio State University and New York University to build precision oncology approaches for the treatment of AML by identifying genetic variants and other genomic factors.
   
• This government initiatives aimed at strengthening healthcare infrastructure that can enhance the care for AML patients. This includes investments in medical facilities, equipment, and training for healthcare professionals.
   

However, innovative and targeted therapies for AML often come with a high price tag. The cost of these novel treatments may limit access for certain patients, particularly in regions or healthcare systems with limited financial resources. Thus, impeding the growth of the market.
 

Acute Myeloid Leukemia Market Analysis

Based on disease type, the global acute myeloid leukemia is segmented into myeloblastic leukemia, myelomonocytic leukemia, promyelocytic leukemia, monocytic leukemia, and other leukemia types. The myeloblastic leukemia segment held the largest market share of 45.2% in 2023.
 

• Myeloblastic leukemia is a common type of acute myeloid leukemia. Their widespread prevalence contributes to a larger potential market. For instance, according to the National Library of Medicine, myeloblastic leukemia accounts for 45% of the total types of the AML. Similarly, the myeloblastic leukemia can be associated with specific genetic mutations or chromosomal abnormalities. Thus, identification of these genetic markers is important for both diagnosis and treatment planning, thereby escalating the growth of the market.
   
• Furthermore, treatment for myeloblastic leukemia typically involves induction chemotherapy to eliminate leukemia cells from the bone marrow. Therefore, advances in chemotherapy, targeted therapy and precision medicine is expected to contribute to significant patient outcomes. Thus, all these factors are driving the dominance of this segment.

Based on treatment type, the global acute myeloid leukemia market is classified into chemotherapy, targeted therapy, immunotherapy, and other treatment types. The chemotherapy segment held the largest market revenue of USD 1.3 billion in 2023.
 

• Chemotherapy works by killing rapidly dividing cells, including acute myeloid leukemia cells. This ablation of abnormal cells is crucial for resetting the bone marrow environment. Thus, it has been the choice of treatment for the patients suffering from AML. Hence, driving the growth of the market.
   
• Further, due to its efficacy and success rate in the treatment of AML, it has attained a notable position in the market. For instance, according to the National Cancer Institute, in 2023, approximately 60 – 70% of adults with AML can be expected to attain complete remission status after appropriate therapy. Therefore, chemotherapy agents can be combined with targeted therapies or other novel agents in evolving treatment strategies. As combinations are designed to improve efficacy and reduce the risk of relapse. Thus, all these factors contribute to the growth of the segment.
   

Based on route of administration, the global acute myeloid leukemia is bifurcated into parenteral and oral. The parenteral segment is expected to reach the largest market revenue of USD 3.5 billion by 2032.
 

• The parenteral route of administration is more efficient and faster in terms of drug action compared to other routes. It also provides the onsite monitoring. Similarly, parenteral route such as, IV administration is common in AML treatment, especially for chemotherapy drugs. This route allows for the rapid and direct delivery of medications into the bloodstream, ensuring systemic distribution throughout the body.
   
• Further, parenteral route of administration bypasses the gastrointestinal tract, which can be beneficial for patients who have difficulty taking medications orally. Thus, boosting the segmental growth.
   

Based on end-user, the global acute myeloid leukemia is segmented into hospitals & clinics, specialty centers, homecare settings, and ambulatory care centers. The hospitals & clinics segment dominated the market in 2023 and is anticipated to grow at CAGR of 9.8% over the forecast years.
 

• Hospitals & clinics are equipped with comprehensive facilities and specialized departments, including hematology-oncology units, where AML patients can receive integrated care. These facilities provide a range of services, from diagnosis to treatment and supportive care.
   
• Additionally, AML treatment often involves a multidisciplinary team of healthcare professionals, including hematologists, oncologists, pathologists, radiologists, and supportive care specialists. Thus, hospitals & clinics are well-suited to facilitate collaboration among these specialists to ensure comprehensive patient care. Thus, escalating the segmental growth.

In 2023, North America held a significant share of 38.4% in the global acute myeloid leukemia market.
 

• U.S. and Canada both comprise relatively high prevalence of AML compared to other country. Therefore, this contributes to mortality and morbidity. For instance, according to the American Society of Cancer, in 2023, about 11,310 deaths from AML occurred in U.S. alone. Thus, increasing AML cases along with significant death occurrence will spur the early diagnosis and treatment regimen, thereby augmenting the market growth.
   
• North America boasts advanced healthcare infrastructure, including state-of-the-art hospitals, research facilities, and specialized cancer treatment centers. This infrastructure supports early diagnosis, comprehensive treatment, and ongoing management of AML.
   

Such aforementioned factors are expected to propel the acute myeloid leukemia in the North American market.
 

Acute Myeloid Leukemia Market Share

The acute myeloid leukemia industry is characterized by diverse players competing in the industry. Pfizer Inc., Novartis AG, Bristol Myers Squibb Company, and Astellas Pharma Inc., account for significant market share. These prominent players adopt a combination of strategic initiatives to provide comprehensive range of products, such as collaboration & partnership, global expansion, research and development, diverse treatment modalities, market access and commercialization, product diversification, and regulatory compliance to maintain a competitive edge in the market.
 

Acute Myeloid Leukemia Market Companies

Foremost players operating in the acute myeloid leukemia industry are as mentioned below

• Astellas Pharma Inc.
• Bristol Myers Squibb Company
• Celgene Corporation
• Daiichi Sankyo Company, Limited
• Jazz Pharmaceuticals plc
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Partner Therapeutics, Inc.
• Pfizer Inc.
• Rigel Pharmaceuticals, Inc.
   

Acute Myeloid Leukemia Industry News

• In June 2021, Bristol Myers Squibb Company received European Commission Approval for Onureg (azacitidine tablets) as frontline oral maintenance therapy for adults with acute myeloid leukemia. This approval increased the sales and product reach of the company.
   
• In November 2018, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved Daurismo (glasdegib), a once-daily oral medicine, for the treatment of newly diagnosed acute myeloid leukemia (AML). Thus, it increased the product diversification of the company.
   

Global acute myeloid leukemia market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

Market, By Disease Type

• Myeloblastic leukemia 
• Myelomonocytic leukemia
• Promyelocytic leukemia
• Monocytic leukemia
• Other leukemia types

Market, By Treatment Type

• Chemotherapy
  • Anti-metabolites
  • Alkylating agents
  • Anthracycline drugs
  • Other chemotherapy types 
• Targeted therapy
• Immunotherapy
• Other treatment types

Market, By Route of Administration

• Parenteral
• Oral

Market, By End-user

• Hospitals & clinics
• Specialty centers
• Homecare settings
• Ambulatory care centers

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa